|
Active substance |
fremanezumab |
|
Holder |
Teva Pharma Belgium N.V./S.A. |
|
Status |
Closed |
|
Public documents |
Prophylaxis of migraine in adult patients who suffer from at least 8 monthly migraine days and who previously failed on at least 3 preventive treatment classes and cannot be satisfactorily treated with the other approved and commercially available alternative treatments, in accordance with clinical guidelines, because of efficacy and/or safety issues. |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
16/02/2021 |
Ajovy®
Last updated on